Lindsey Shapiro, PhD, science writer —

Adults and children with endogenous Cushing’s syndrome in Colombia will have access to Metopirone (metyrapone), the first Cushing’s treatment to be approved in the country, HRA Pharma Rare Diseases, which developed and markets the treatment, announced. With this registration, Colombia joins several other countries, including in Europe, the…

Long-term treatment with Recorlev (levoketoconazole) safely leads to sustained reductions in cortisol levels, disease signs and symptoms, and improvements in quality of life in adults with endogenous Cushing’s syndrome, according to nearly two years of data from the Phase 3 SONICS trial. Treatment benefits were generally maintained or deepened…

Isturisa (osilodrostat) led to sustained reductions in cortisol levels in people with Cushing’s disease over nearly seven years of treatment in an extension phase of the Phase 2 LINC-2 trial. Cardiovascular symptoms were also well controlled throughout the study and no new safety signals were detected. “These data…

Patients who undergo surgery for Cushing’s syndrome may have a high risk of blood clots and should receive preventive anti-blood clotting treatments for at least one month, according to a recent case report. Researchers also suggested these patients should be closely monitored following surgery. The report described the case of…

Prolonged exposure to the hormone cortisol during periods of active disease in Cushing’s patients is linked to lower long-term quality of life but not to cognitive problems after remission, a study shows. The study, “Impaired quality of life, but not cognition, is linked to a history of chronic…

Certain molecules called microRNAs (miRNAs) that act to regulate protein production could underlie certain Cushing’s syndrome subtypes, a study found. Better understanding the role of these miRNAs and the proteins they affect will help facilitate a better understanding of disease processes, as well as the development of better treatments for…

Metopirone (metyrapone) and Isturisa (osilodrostat) were both effective at controlling cortisol levels in people with endogenous Cushing’s syndrome over a 12-week period, according to a recent study. However, Isturisa tended to lower cortisol levels faster, and appeared to be better at controlling blood pressure than Metopirone. Some heart…

Undergoing a surgical removal of the adrenal glands — called adrenalectomy — was associated with a better prognosis than cortisol-suppressing therapies alone in people with ectopic Cushing’s syndrome (ECS) caused by a neuroendocrine tumor (NET), according to a recent report. Patients who received an ectopic Cushing’s diagnosis after being found…